Fatty liver index and cardiovascular outcomes in never-treated hypertensive patients: a prospective cohort
- 14 October 2022
- journal article
- research article
- Published by Springer Nature in Hypertension Research
- Vol. 46 (1) , 119-127
Abstract
The prevalence of nonalcoholic fatty liver disease (NAFLD) has been increasing rapidly worldwide, affecting 25–30% of the population. Fatty liver index (FLI) is a validated marker of NAFLD and can be used as a screening tool for hepatic steatosis. The purpose of the study was to evaluate the relationship between FLI and the risk of major cardiovascular events in never treated hypertensive patients. We included 903 hypertensive patients without a history of cardiovascular disease (mean age 52.7 ± 11.4 years; men 55%; baseline clinic BP 149.8 ± 15.2/95.5 ± 10.1 mmHg). Participants were prospectively evaluated for a mean follow-up period of 5.2 ± 3.2 years with at least one annual visit. Patients were also categorized into two groups using an FLI of 60 units. The incidence of cardiovascular events during follow-up was 8.5% (n = 77). Patients with FLI < 60 (n = 625) had a better BP control compared to their counterparts with FLI ≥ 60 (n = 278) during follow up (43% vs 33%, p = 0.02). Cox-regression analysis indicated that FLI (Hazard Ratio [HR], 1.05; 95% Confidence Interval [CI], 1.03–1.07, p < 0.001), FLI z-scores (HR, 3.66; 95% CI, 2.22–6.04) and high-risk FLI (HR, 7.5; 95% CI, 3.12–18.04) were independent determinants of the outcome after adjustment for baseline and follow-up variables. Stratification by diabetes mellitus indicated that FLI predicted the outcome to a greater extent in those with than those without diabetes (P-interaction < 0.001). In conclusion, FLI has an independent prognostic value for the incidence of cardiovascular events in newly diagnosed, never-treated hypertensive patients. Therefore, FLI might identify higher-risk patients in the primary prevention of hypertension.Keywords
This publication has 20 references indexed in Scilit:
- Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated?European Journal of Gastroenterology & Hepatology, 2018
- Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver diseaseCellular and Molecular Life Sciences, 2018
- Time to step‐up the fight against NAFLDHepatology, 2018
- Cumulative in-trial and post-trial effects of blood pressure and lipid loweringJournal Of Hypertension, 2017
- Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studiesJournal Of Hypertension, 2017
- A Prospective Study of Fatty Liver Index and Incident Hypertension: The KoGES-ARIRANG StudyPLOS ONE, 2015
- European Society of Hypertension Position Paper on Ambulatory Blood Pressure MonitoringJournal Of Hypertension, 2013
- Devil and angel in the renin–angiotensin system: ACE–angiotensin II–AT1 receptor axis vs. ACE2–angiotensin-(1–7)–Mas receptor axisHypertension Research, 2009
- Relationship between Glomerular Filtration Rate and the Prevalence of Metabolic Abnormalities: Results from the Third National Health and Nutrition Examination Survey (NHANES III)Nephron Clinical Practice, 2007
- The renin–angiotensin–aldosterone system, glucose metabolism and diabetesTrends in Endocrinology & Metabolism, 2005